Hoth Therapeutics, Inc. (HOTH): Price and Financial Metrics


Hoth Therapeutics, Inc. (HOTH): $3.91

-0.09 (-2.25%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

HOTH Stock Price Chart Interactive Chart >

Price chart for HOTH

HOTH Price/Volume Stats

Current price $3.91 52-week high $43.75
Prev. close $4.00 52-week low $3.47
Day low $3.90 Volume 12,200
Day high $4.06 Avg. volume 124,970
50-day MA $6.23 Dividend yield N/A
200-day MA $10.86 Market Cap 5.08M

Hoth Therapeutics, Inc. (HOTH) Company Bio


Hoth Therapeutics, Inc. is a development stage biopharmaceutical company, which engages in the provision and development of therapeutic platform. The company focuses on the patients suffering from conditions such as atopic dermatitis, also known as eczema. It offers BioLexa Platform, a proprietary, patented, drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern in May 2017 and is headquartered in New York, NY.


HOTH Latest News Stream


Event/Time News Detail
Loading, please wait...

HOTH Latest Social Stream


Loading social stream, please wait...

View Full HOTH Social Stream

Latest HOTH News From Around the Web

Below are the latest news stories about HOTH THERAPEUTICS INC that investors may wish to consider to help them evaluate HOTH as an investment opportunity.

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it received written notice from the NASDAQ Stock Market LLC (NASDAQ) on November 9, 2022, informing the Company that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on the NASDAQ Capital Market.

Yahoo | November 9, 2022

Hoth Therapeutics Up After Positive Clinical Data For BioLexa

Hoth Therapeutics (NASDAQ: HOTH) was on an upward trajectory in morning trading on Monday as the biopharmaceutical company announced positive data for BioLexa in a Phase 1b clinical trial. BioLexa is an investigational therapeutic in adult patients with mild-to-moderate atopic dermatitis. BioLexa indicated a significant improvement in the severity of the disease as measured by SCORAD (SCORing Atopic Dermatitis) and EASI scale. The SCORAD scale measures the severity of atopic dermatitis. Using the EASI scale, "100% of patients showed clinically relevant improvement >50% compared to Day 1 during the entire 28-day study treatment period.

Shrilekha Pethe on TipRanks | October 31, 2022

Why Is Hoth Therapeutics (HOTH) Stock Up 24% Today?

Hoth Therapeutics (HOTH) stock is rising higher on Monday with heavy trading and positive results from a Phase 1 clinical trial of BioLexa.

William White on InvestorPlace | October 31, 2022

Hoth Therapeutics' Atopic Dermatitis Candidate Shows Improvement In Severity, Shares Jump

Hoth Therapeutics Inc (NASDAQ: HOTH) announced Phase 1b trial data for BioLexa in adult patients with mild-to-moderate atopic dermatitis. Using the SCORAD as a clinical tool for assessing the severity of atopic dermatitis (scale) and EASI score, a tool used to measure the extent (area) and severity of atopic eczema, all patients showed improvement during the study compared to the day one score. Using the EASI scale, 100% of patients showed clinically-relevant improvement >50% compared to Day 1 d

Yahoo | October 31, 2022

HOTH THERAPEUTICS REPORTS POSITIVE BIOLEXA PHASE 1B CLINICAL TRIAL RESULTS IN MILD TO MODERATE ATOPIC DERMATITIS

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced positive data for BioLexa, its investigational therapeutic in a Phase 1b clinical trial in adult patients with mild-to-moderate atopic dermatitis.

Yahoo | October 31, 2022

Read More 'HOTH' Stories Here

HOTH Price Returns

1-mo -10.73%
3-mo N/A
6-mo -62.66%
1-year -79.01%
3-year -96.48%
5-year N/A
YTD -76.30%
2021 -72.16%
2020 -61.71%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7058 seconds.